BioCentury
ARTICLE | Finance

Building bispecifics

Why investors backed bispecifics play EpimAb with $25M series A round

April 29, 2017 12:21 AM UTC

Encouraging preclinical data and a broadly applicable bispecifics platform helped Shanghai-based EpimAb Biotherapeutics Inc. attract $25 million in series A funding from a syndicate of Chinese, U.S. and U.K. investors.

"Most biologics companies in China are based on proprietary single molecules, but EpimAb is based on a broadly applicable technology platform," said Ning Li of Oriza Seed Capital, which led the round...

BCIQ Company Profiles

EpimAb Biotherapeutics Inc.

BCIQ Target Profiles

EGFR